Drug Profile

Pegorgotein

Alternative Names: Dismutec; PEG-SOD; PEG-superoxide dismutase; Polyethylene glycol superoxide dismutase; WIN 22118

Latest Information Update: 26 Aug 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Enzon Pharmaceuticals
Class Oxidoreductases; Polyethylene glycols
Mechanism of Action Free radical scavengers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Craniocerebral trauma; Reperfusion injury; Stroke

Most Recent Events

11 Jul 1997 Discontinued - Clinical trials for Stroke (unspecified route)
08 Jul 1997 Sanofi Winthrop is no longer a licensee for pegorgotein
08 Jul 1997 Discontinued-III for Head injuries in France (IV)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com